Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKinsey
McKesson
Johnson and Johnson
Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ramucirumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Ramucirumab: Patents, clinical trial progress, indications

Ramucirumab is an investigational drug.

There have been 95 clinical trials for Ramucirumab. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2017.

The most common disease conditions in clinical trials are Adenocarcinoma, Esophageal Neoplasms, and Stomach Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.

There are thirty-three US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Ramucirumab
TitleSponsorPhase
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)Eli Lilly and CompanyPhase 2
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)Merck Sharp & Dohme Corp.Phase 2
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)Masahiro TsuboiPhase 2

See all Ramucirumab clinical trials

Clinical Trial Summary for Ramucirumab

Top disease conditions for Ramucirumab
Top clinical trial sponsors for Ramucirumab

See all Ramucirumab clinical trials

US Patents for Ramucirumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ramucirumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Ramucirumab   Start Trial Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. (Menlo Park, CA)   Start Trial
Ramucirumab   Start Trial Mesalamine for the treatment of cancer Cipla Limited (Mumbai, IN)   Start Trial
Ramucirumab   Start Trial Heterocyclic compound and pharmaceutical composition comprising same BEYONDBIO INC. (Daejeon, KR)   Start Trial
Ramucirumab   Start Trial Combination therapy for cancer Eli Lilly and Company (Indianapolis, IN)   Start Trial
Ramucirumab   Start Trial Constructs having a SIRP-.alpha. domain or variant thereof ALX ONCOLOGY INC. (Burlingame, CA)   Start Trial
Ramucirumab   Start Trial Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent Almac Diagnostics Limited (Craigavon, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ramucirumab

Drugname Country Document Number Estimated Expiration Related US Patent
Ramucirumab Australia 2013220749 2032-02-15   Start Trial
Ramucirumab Brazil 112014019627 2032-02-15   Start Trial
Ramucirumab Canada 2862476 2032-02-15   Start Trial
Ramucirumab China 104114705 2032-02-15   Start Trial
Ramucirumab China 108570468 2032-02-15   Start Trial
Ramucirumab European Patent Office 2814963 2032-02-15   Start Trial
Ramucirumab India 5670DEN2014 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
McKinsey
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.